BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
Status:
Terminated
Trial end date:
2019-02-11
Target enrollment:
Participant gender:
Summary
This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in
treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or
amplified head and neck cancer that has returned after a period of improvement. BGJ398 may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.